MDK34597 | CAS#371934-59-7 | PI3K inhibitor

MedKoo Cat#: 406982 | Name: MDK34597

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MDK34597 is a PI3K inhibitor. MDK34597 has CAS#371934-59-7, the last 5 digits of which were used for its name. MDK34597 is an analog of PI-103 and acts as a dual PI3K/mTOR Inhibitor.

Chemical Structure

MDK34597

CAS#371934-59-7

Theoretical Analysis

MedKoo Cat#: 406982

Name: MDK34597

CAS#: 371934-59-7

Chemical Formula: C19H17N5O2

Exact Mass: 347.1382

Molecular Weight: 347.38

Elemental Analysis: C, 65.69; H, 4.93; N, 20.16; O, 9.21

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 650.00	2 Weeks
1g	USD 3,450.00	3-4 Weeks
2g	USD 6,250.00	3-4 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MDK34597; MDK-34597; MDK 34597. PI3K inhibitor.

IUPAC/Chemical Name

3-[4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-benzenamine

InChi Key

RQPKSOWRJPRYCN-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H17N5O2/c20-13-4-1-3-12(11-13)17-22-15-14-5-2-6-21-19(14)26-16(15)18(23-17)24-7-9-25-10-8-24/h1-6,11H,7-10,20H2

SMILES Code

NC1=CC=CC(C2=NC(N3CCOCC3)=C(OC4=NC=CC=C45)C5=N2)=C1

Appearance

Yellow or orange crystalline powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 347.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Geng X, Xie L, Xing H. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo. Technol Cancer Res Treat. 2016 Oct;15(5):716-22. doi: 10.1177/1533034615597366. PubMed PMID: 26224681. 2: Saw S, Arora N. PI3K and ERK1/2 kinase inhibition potentiate protease inhibitor to attenuate allergen induced Th2 immune response in mouse. Eur J Pharmacol. 2016 Apr 5;776:176-84. doi: 10.1016/j.ejphar.2016.02.050. PubMed PMID: 26905476. 3: Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget. 2015 May 10;6(13):11061-73. PubMed PMID: 25857298; PubMed Central PMCID: PMC4484439. 4: Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S. A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol. 2016 Nov 1. pii: mdw562. [Epub ahead of print] PubMed PMID: 27803006. 5: Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int. 2016 Sep;118(3):408-15. doi: 10.1111/bju.13415. PubMed PMID: 26779597. 6: Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 Nov;15(11):2553-2562. PubMed PMID: 27496136. 7: Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak AR, Stayner LA, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infante JR. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 2016 Dec;34(6):740-749. PubMed PMID: 27450049. 8: Ji F, Liu X, Wu Y, Fang X, Huang G. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts. Drug Des Devel Ther. 2015 Oct 19;9:5697-704. doi: 10.2147/DDDT.S89410. PubMed PMID: 26543351; PubMed Central PMCID: PMC4622552. 9: Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549. PubMed PMID: 26909613; PubMed Central PMCID: PMC4914348. 10: Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. PubMed PMID: 25977343; PubMed Central PMCID: PMC4558307. 11: Gravina GL, Mancini A, Scarsella L, Colapietro A, Jitariuc A, Vitale F, Marampon F, Ricevuto E, Festuccia C. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumour Biol. 2016 Jan;37(1):341-51. doi: 10.1007/s13277-015-3725-3. PubMed PMID: 26219891. 12: Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemother Pharmacol. 2016 Dec;78(6):1269-1281. PubMed PMID: 27837257; PubMed Central PMCID: PMC5114336. 13: Zhu Y, Shah K. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther. 2014 Jun 1;15(6):815-22. doi: 10.4161/cbt.28585. PubMed PMID: 24658109; PubMed Central PMCID: PMC4049797. 14: Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. Gynecol Oncol. 2015 Aug;138(2):323-31. doi: 10.1016/j.ygyno.2015.05.031. PubMed PMID: 26033306. 15: Peng Y, Li L, Huang M, Duan C, Zhang L, Chen J. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Cell Signal. 2014 Dec;26(12):2782-92. doi: 10.1016/j.cellsig.2014.08.021. PubMed PMID: 25193113. 16: Rehan M. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model. 2015 Nov;62:226-34. doi: 10.1016/j.jmgm.2015.10.005. PubMed PMID: 26500112. 17: Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ. The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes Cancer. 2016 Mar;7(3-4):73-85. doi: 10.18632/genesandcancer.100. PubMed PMID: 27382432; PubMed Central PMCID: PMC4918946. 18: Tu XK, Zhang HB, Shi SS, Liang RS, Wang CH, Chen CM, Yang WZ. 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. Neurochem Res. 2016 Oct;41(10):2779-2787. PubMed PMID: 27380038. 19: Hayashida Y, Ikeda Y, Sawada K, Kawai K, Kato T, Kakehi Y, Araki N. Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor. Int J Cancer. 2016 Aug 1;139(3):700-11. doi: 10.1002/ijc.30097. PubMed PMID: 26989815. 20: Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J, Zhi X, Zhang J. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis. 2015 Dec 17;6:e2020. doi: 10.1038/cddis.2015.363. PubMed PMID: 26673665; PubMed Central PMCID: PMC4720896.